featured
Dr. Warren Heymann on Avoiding Brimonidine and Oxymetazoline as Hemostatic Agents
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Shagalov DR, Taylor D, Schleichert R, Weiss J, Weiss E. Association of central nervous system depression with topical brimonidine when used for hemostasis: A serious adverse event. JAMA Dermatol. 2017:153:575-7.
- Gill K, Bayart C, Desai R, Golden A, Raimer P, Tamburro J. Brimonidine toxicity secondary to topical use for an ulcerated hemangioma. Pediatr Dermatol. 2016;33:e232-4.
- García-Sevilla JA, Padró D, Giralt MT, Guimón J, Areso P. Alpha 2-adrenoreceptor-mediated inhibition of platelet adenylate cyclase and induction of aggregation in major depression. Effect of long-term cyclic antidepressant drug treatment. Arch Gen Psychiatry. 1990;47:125-32.
- Phillips CB, Huang CC. Topical oxymetazoline hydrochloride 0.05% as a strategy to reduce intraoperative wound oozing in Mohs micrographic surgery. Dermatol Surg. 2015;41:749-50.
- Fabi M, Formigari R, Picchio FM. Are nasal decongestants safer than rhinitis? A case of oxymetazoline-induced syncope. Cardiol Young. 2009;19:633-4.
- Shanler SD, Ondo AL. Arch Dermatol. 2007;143:1369-71.